PREV PreveCeutical Medical Inc.
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development of preventive and therapeutic products derived from organic and nature-identical compounds; synthesized Nature Identical; Sol-Gel Nose-to-Brain delivery platform for Parkinson's disease; develops cannabinoid-based nose-to-brain delivery system for the relief of a various ailments, including pain, inflammation, seizures, and neurological disorders; peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment, and determinations in animal models of pain and inflammation; and non-addictive analgesic peptides for pain management. It also involved in licensing, branding, and marketing nutraceutical and wellness products; Sol-Gel platform; and peptide program. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.…
Industry Peers
BiotechnologyKey Statistics
About PreveCeutical Medical (CNSX: PREV)
›
PreveCeutical Medical (CNSX: PREV) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0200 CAD on 19 November 2026, down 42.9% over 52 weeks. Its 52-week range is 0.0150 CAD to 0.0600 CAD: the price is 66.7% below the high and 33.3% above the low.
Its market capitalisation is 12.76M CAD.
PreveCeutical Medical reports return on equity of 27.1% and an operating margin of 0.0%.
Its debt exceeds its cash by 4.81M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.